The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•23 April 2026•

1 min read

Atrium Therapeutics Earns $15M Milestone Payment from Bristol Myers Squibb

Key Facts

1Atrium Therapeutics announced it earned a $15 million milestone payment from Bristol Myers Squibb under their collaboration.

2The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication.

Atrium Therapeutics has successfully secured a $15 million milestone payment from Bristol Myers Squibb under their ongoing global collaboration agreement. The payment was triggered by the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication. This achievement validates Atrium's RNA-based platform and its technical progress in developing innovative cardiovascular treatments. While the payment amount is relatively modest for a pharmaceutical giant like BMY, it represents a significant operational boost for Atrium. The partnership highlights the continued focus of both companies on addressing unmet needs in heart disease through advanced biotechnology. This cash inflow is expected to support Atrium's research and development pipeline moving forward.